1 to 4 of 4 literature results

• Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.

  Impaired transduction of transforming growth factor-beta signaling has recently been implicated in Alzheimer disease. Transforming growth factor-beta …

  Authors: Katy A Chalmers, Seth Love

  Source: Journal of neuropathology and experimental neurology. 2007 Nov

  View Full Text

• Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons.

  Transforming growth factor (TGF)-beta is a multifunctional cytokine with anti-inflammatory, reparative and neuroprotective functions. Increased levels…

  Authors: Katy A Chalmers, Seth Love

  Source: Journal of neuropathology and experimental neurology. 2007 Feb

  View Full Text

• Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease.

  Cholinesterase inhibitors (ChEIs) are widely used for the symptomatic treatment of Alzheimer's disease (AD). In vitro and in animal studies, ChEIs hav…

  Authors: Katy A Chalmers, Gordon K Wilcock, Harry V Vinters, Elaine K Perry, Robert Perry, Clive G Ballard, Seth Love

  Source: Journal of neurology. 2009 May

  View Full Text

• APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease.

  Polymorphisms in the APOE promoter, ACE1 and CYP46 genes have all been reported to be associated with Alzheimer's disease (AD). We studied the relatio…

  Authors: Katy A Chalmers, Doris Culpan, Patrick G Kehoe, Gordon K Wilcock, Anthony Hughes, Seth Love

  Source: Neuroreport. 2004 Jan 19

  View Full Text